Quest Diagnostics shares trail S&P 500 over 52 weeks despite 2026 outlook hike

Quest Diagnostics (DGX) reported Q1 2026 revenue of $2.9 billion, up 9.2% year over year, and adjusted EPS of $2.50, a 13.1% increase. The company also raised its full-year adjusted EPS guidance to $10.63–$10.83. DGX is up 12.4% year to date versus the S&P 500’s 9.6% gain, but remains down 8.7% from its 52-week high and has recently lagged the broader market. The stock has held above its 200-day moving average, while analysts rate it “Moderate Buy” with a mean target of $223, implying 14.4% upside.